RT Journal Article
SR Electronic
T1 Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13)
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3121
OP 3126
DO 10.21873/anticanres.15096
VO 41
IS 6
A1 MAYUKO MIKI
A1 SHINTARO TAKAO
A1 MUNEHARU KONISHI
A1 YASUSHI SHIGEOKA
A1 MASARU MIYASHITA
A1 HIROFUMI SUWA
A1 YASUO MIYOSHI
A1 KOICHI HIROKAGA
A1 TOSHITAKA OKUNO
A1 KAZUHIKO YAMAGAMI
A1 MICHIKO IMAMURA
A1 KEIKO MURASE
A1 AYAKO YANAI
A1 HIROKAZU TANINO
YR 2021
UL http://ar.iiarjournals.org/content/41/6/3121.abstract
AB Background/Aim: S-1, a 5-fluorouracil(5-FU) oral anti-cancer drug, has been traditionally used with a schedule of 4-week oral administration followed by 2-week rest for breast cancer treatment. We, herein, aimed to investigate the clinical efficacy and safety of a schedule of 2-week oral administration followed by 1-week rest for patients with metastatic breast cancer. Patients and Methods: We enrolled patients with HER2-negative metastatic breast cancer who had not received prior chemotherapy. S-1 was administered consecutively for 2-weeks followed by a 1-week rest. Results: Between September 1, 2013 and August 31, 2016, 32 patients were enrolled. The median follow-up time was 32.1 months. The median progression-free survival (PFS) was 9.4 months. Overall survival (OS) was 41.0 months, time to treatment failure (TTF) was 7.8 months, response rate (RR) was 31.3%, and disease control rate (DCR) was 78.1%. The incidence of grade 3 side-effects was not high. Conclusion: The 3-week schedule of S-1 can be considered useful as a treatment for patients with metastatic breast cancer, helping in maintaining a high quality of life.